Physiological Role
Homocysteine is a sulfur-containing amino acid produced at the crossroads of the methionine cycle. This cycle generates S-adenosylmethionine (SAM), the body's universal methyl group donor. SAM is involved in over 200 enzymatic reactions, from gene regulation to neurotransmitter synthesis.
Two metabolic pathways eliminate homocysteine. Remethylation converts it back to methionine using folate (vitamin B9) and vitamin B12. Transsulfuration transforms it into cysteine via vitamin B6. Both pathways work in parallel to keep homocysteine levels low.
When B vitamin intake is insufficient or a genetic polymorphism slows one of these pathways, homocysteine accumulates in plasma. Its level therefore simultaneously reflects the status of three essential cofactors and the proper functioning of the cellular methylation machinery.
Reference Ranges
These reference ranges are derived from scientific literature and may differ from your laboratory's reference values.
Biological Significance
Homocysteine levels in the optimal zone indicate the methylation cycle is functioning efficiently. Vitamin cofactors (B9, B12, B6) are present in sufficient quantities to ensure proper recycling of this amino acid. This profile is associated with better vascular integrity and lower cognitive risk.
Elevated values signal a slowdown in the methylation cycle. Several scenarios may explain this. Insufficient folate or vitamin B12 intake is the most common cause. An MTHFR gene polymorphism may also slow folate conversion to its active form. Cross-reading with vitamin B9 and B12 levels helps identify the source of imbalance.
Homocysteine is a marker that gains relevance with repetition. A single measurement may reflect a transient variation linked to recent diet. Monitoring over several assessments, spaced three to six months apart, reveals the underlying trend and confirms the body's response to nutritional adjustments.
The trajectory matters as much as the point-in-time value. A level that gradually decreases across assessments confirms that methylation cycle cofactors are being properly supplied. A level that plateaus despite adequate intake may point toward other factors worth exploring with a healthcare professional.
Influencing Factors
Diet. Folate comes primarily from leafy green vegetables, legumes and citrus fruits. A diet low in these foods reduces vitamin B9 availability, a direct cofactor in homocysteine recycling. Vitamin B12 is supplied by animal proteins. Unsupplemented vegan diets carry an increased risk of elevated levels.
Genetics. The MTHFR C677T polymorphism is present in homozygous form in 8 to 10% of Europeans. It reduces the activity of the enzyme that converts folate to its active form. Carriers of this variant have increased methylfolate requirements to maintain favorable homocysteine levels.
Age and sex. Homocysteine naturally increases with age, particularly after menopause in women. Men generally have slightly higher levels than women of childbearing age.
Kidney function. The kidneys participate in homocysteine clearance. Impaired kidney function can contribute to its accumulation, independently of vitamin status.
Lifestyle. Regular tobacco use and sedentary behavior are associated with higher levels. Regular physical activity helps maintain a more favorable metabolic profile.
Supplementation. Vitamin B9, vitamin B12 and vitamin B6 (P5P) are the three cofactors of the methylation cycle. Adequate intake of these vitamins contributes to normal homocysteine metabolism. Trimethylglycine (TMG) is a methyl group donor that participates in an alternative homocysteine remethylation pathway.
Medications. Certain medications (methotrexate, antiepileptics, proton pump inhibitors) can interfere with B vitamin metabolism and contribute to elevated homocysteine.
In the Singular Formula
Homocysteine holds a central role in Singular formula personalization. This biomarker triggers a set of adjustment rules that modulate the dosages of three key methylation cycle cofactors.
When homocysteine falls in the elevated zone, vitamin B6 (P5P) dosage is increased. Vitamin B6 is involved in transsulfuration, the second pathway for homocysteine elimination. If vitamin B12 levels are simultaneously low, vitamin B12 dosage is also increased to support the remethylation pathway. Similarly, insufficient vitamin B9 levels alongside elevated homocysteine trigger a higher vitamin B9 dosage.
When homocysteine is elevated but vitamin B9 and B12 are already in the optimal zone, the logic shifts. The formula then includes a moderate supply of vitamin B9 and vitamin B12 to support the cycle without excess. This graduated logic reflects the calibration principle that guides the formulation engine.
Trimethylglycine (TMG), a methyl group donor included in the Singular formula, participates in an alternative homocysteine remethylation pathway. Homocysteine is also read alongside mean corpuscular volume (MCV), vitamin B9 and vitamin B12 for an integrative assessment of methylation status.
Linked Bioactives
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Homocysteine Studies Collaboration | 2002 | Meta-analysis | JAMA | View on PubMed |
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis Meta-analysis of 30 prospective and retrospective studies covering 5,073 coronary events and 1,113 strokes. A 25% lower homocysteine level was associated with an 11% lower coronary risk and 19% lower stroke risk. | ||||
| Wald DS et al. | 2002 | Meta-analysis | BMJ | View on PubMed |
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis Meta-analysis combining 72 genetic studies and 20 prospective studies. A 3 µmol/L reduction in homocysteine was associated with a 16% lower risk of ischemic heart disease and 24% lower stroke risk. | ||||
| Huo Y et al. | 2015 | Randomised Controlled Trial | JAMA | View on PubMed |
Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial Randomized clinical trial involving 20,702 hypertensive adults. Adding folic acid to antihypertensive treatment reduced first stroke risk by 21% compared to treatment alone. | ||||
| Smith AD et al. | 2010 | Randomised Controlled Trial | PLoS One | View on PubMed |
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial Randomized controlled trial (VITACOG) on 271 subjects with mild cognitive impairment. B9, B12 and B6 supplementation reduced brain atrophy rate by 30%, and by 53% in subjects with homocysteine above 13 µmol/L. | ||||
| Douaud G et al. | 2013 | Randomised Controlled Trial | Proc Natl Acad Sci U S A | View on PubMed |
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment Secondary MRI analysis of the VITACOG trial. B vitamin supplementation slows gray matter atrophy in vulnerable brain regions, with an effect proportional to baseline homocysteine levels. | ||||
| Esse R et al. | 2019 | Systematic Review | Int J Mol Sci | View on PubMed |
The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art Comprehensive review of the mechanisms by which homocysteine impairs endothelial function: oxidative stress, reduced nitric oxide bioavailability, activation of pro-inflammatory and prothrombotic pathways. | ||||
| Ganguly P et al. | 2015 | Systematic Review | Nutr J | View on PubMed |
Role of homocysteine in the development of cardiovascular disease Review of mechanisms linking homocysteine to cardiovascular risk: endothelial dysfunction, smooth muscle cell proliferation and vascular extracellular matrix alteration. | ||||